FDA panel votes against approval of GSK's lung disease drug

A U.S. Food and Drug Administration expert panel on Wednesday did not support approval of GlaxoSmithKline Plc's drug Nucala in treating a disease that limits airflow to the lungs.

from Reuters: Health https://ift.tt/2LCxrsg
via IFTTT

• Tweet
• Share
• Share
• Share
• Share